Following a sale process that attracted strong interest across Europe and from Northern America, DDA&Company is proud to announce that Extens, a French private equity firm specialized in healthcare IT, acquired Bow Medical in an LBO deal with the support of its management.

Founded in 1999, Bow Medical is the developer of Diane, a software suite dedicated to Anesthesia, Intensive Care, and Maternity Care. Historically conceived for Anesthesia services, in which Bow Medical is the independent leader, the Diane suite has progressively expanded to Intensive Care and Maternity Care. Providing a broad and deep coverage, Diane enables its clients to :

  • Centralize patient pathways
  • Alleviate nurses and physicians from time consuming administrative tasks to let them focus on their patients
  • Improve patient safety and quality of care

More than 260 hospitals, public and private, such as CHU de Lille, Assistance Publique – Hôpitaux de Paris, le CHU de Lille, les hospices civils de Lyon et Ramsay GDS have already chosen Diane to equip their 2,600 operating rooms and ICUs.

Extens, now a majority shareholder, will continue the international expansion and development of the suite’s features.

The senior tranche of the debt was syndicated to Crédit du Nord, acting as lead arranger, and Société Générale.

Alexandre Largillière, President of Bow Medical: “We are thrilled to join Extens and continue contributing directly to the development of Bow Medical. Since the founding of the company, we have prepared ourselves to hand over the reigns of the company to a new executive team for its third stage since it was founded by our father, Serge Largillière.”

Dominique Mercier, Managing Director Extens: “Bow Medical can now become a European leader of patient’s pathway from the ER’s critical care to the OR, and from anesthesia to intensive care, while accompanying patients outside the clinic. Diane equips 2,600 operating rooms and soon 400 ICU beds. Its establishment outside of France will contribute to reinforce the patients’ safety during the critical phases of a treatment.”